Index

Alternative assets, 14
American Capital, 259, 263–264, 275–276
Australia, 400, 405, 406, 407, 409
Australasian private equity market, 395

Benchmarking performance, 287–288, 290–297
advanced private equity benchmarking, 293–297
based on deal-level benchmarks, 293–294
alternative techniques, 292
public market benchmarks, using and interpreting, 291–292
traditional benchmarking approach, shortcomings of, 290–291
Blackstone Group, 41, 43–44
British Venture Capital Association (BVCA), 339, 381–382, 467–468
Buyouts, international syndication of, 408–410

CalPERS, 272, 274, 276, 336, 342–343
Canada, venture capital and private equity in, 579–602
multivariate regression evidence, 588–598
capital-raising hurdles, 588–594
time to failure, 594–596
value-added, extent of, 596–598
2008 YORKbiotech survey data, description of, 582–588
Capital Asset Pricing Model (CAPM), 20–21
“Cash drag,” 58
Claw-backs, 372
Cobb-Douglas production functions, 303
Companies Act
1928/1929, 498
1948, 499
1981, 499
1985, 499
2006, 500
CompuDyne Corporation, 123–124
Contractual arrangements, 368–379
limited partnership structure, 369–373
relationship between the fund and its portfolio companies, 376–379
restrictive covenants, 373–376
Convertible stock, 377

Denmark, private equity in, 555–578
history of buyouts, 556–558
portfolio companies, consequences for capital structure of, 558–565
case studies, 563–564
empirical investigation, 560–563
investments, financial performance of, 564
leverage and takeovers, 558
private equity funds, capital structure of, 559–560
tax payments, implications for, 565–575
complications, 573–575
hypothetical case, 572–573
implications for corporate tax payments, 567–571
private equity takeover, example of, 566–567
private equity takeovers, wider tax implications of, 571–572
taxes and takeovers, 565–566
Deutsche Borse (German stock exchange), 160, 163, 512, 517
Disclosure and fund reporting, enhancing, 386–387
Econometric analysis and modeling, 213–218
Efficient markets hypothesis, 302
Emerging markets, private equity in, 410–411, 419–436
determinants of, 421–424
importance of allocation criteria, survey among institutional investors on, 424–432
investors’ preferences regarding different emerging regions, 431–432
perceptions of particular allocation criteria, 429–431
international comparison, 420–421
Employment Retirement Income Stabilization Act (1979), 438
Employment, wage, and productivity effects of transactions, 311–332
employment and productivity identities, 313–315
empirical studies
U.K., 323–327
U.S., 315–323
Endowments, 10, 11, 12
Europe, private equity in, 437–461
history, 438–439
internationalization of private equity, 446–450
investment, 441–446
divestment at cost, 446
evolution activity flows, 442
fund-raising, 444
industrial sectors, 445
investment benchmarks database, 442
stage distribution of investments, 443
performance, 450–456
evidence, 453–456
literature, 450–451
measures, 451–453
structure of, 439–441
European Venture Capital Association (EVCA), 339, 384–385, 441, 453, 457, 467–468
Fama-French model, 21–23
Financial Service Authority (U.K.), 385–386
Fortress Investment Group, 40, 43–44
Foundations, 10, 11, 12
France, 400, 402, 403, 404, 407, 408, 409
Franklin Mutual Advisers, 168
Fund-of-funds, 10, 11, 12, 14, 16, 397
Fund-raising
international, brief overview of, 396–398
methods
nontraditional, 38–39
traditional, 36–38
patterns, 34
of buyout funds, 35
of European private equity firms, 36
Generalized Method of Moments (GMM), 267, 269
Generally accepted accounting principles (GAAP), 338
Geometric returns, 266–267
German stock exchange (Deutsche Borse), 160, 163, 512, 517
Germany, 388–389, 400, 401, 402, 403, 404, 405, 407, 408, 409
investments according to financing stages in, 1990–2007, 526, 527
by industry, 1990–2007, 522
by states, 1990–2007, 524
private equity market, 401
regulatory responses to hedge fund and private equity in, 388–389
venture capital and private equity in, 511–553
German venture capital industry, development of, 513–534
going public as exit route for venture capital and performance of venture-backed IPOs, 534–548
Governance and investor protection, 387
Hedge funds’ activism, 155–193
approach to activism, 159–162
incumbent management, how hedge funds engage a fight against, 163–167
stake owned, wolf packs, empty voting, and hidden ownership, 165–167
market data and trends toward convergence, 156–159
private equity and hedge funds, 157–159
targeted companies, features of, 162–163
Hurdle rate, 440
Icahn, Carl, 156, 160, 161, 163
versus Time Warner, Inc., clinical study of, 167–182
activist intervention, 172–174
event study analysis, 177–182
parties involved, 168–172
path followed, 174
Institutional investment in private equity, 9–29
corporate, 13
government entities, 13
motivation for
key features of, 11
nonfinancial, 13
INDEX

International private equity flows, 395–417
fund-raising, brief overview of, 396–398
investments of private equity funds in western Europe, North America, and Australia, 398–410
international syndication of buyouts, 408–410
investor countries, most important, 399–402
median and average values of nondomestic investments, annual trend of, 403
regional clustering of investment market, 406–408
target countries, most important, 402–406
private equity in emerging markets, 410–411
International Private Equity and Venture Capital Valuation Guidelines, 340–341
IPOs, 31–51, 238–239, 458
fund-raising methods
nontraditional, 38–39
traditional, 36–38
private equity
industry, recent trends in, 33–36
performance and implications for the future, 39–44
sovereign wealth funds complementing and substituting for, 45–48
Italy, 400, 402, 403, 404, 405
private equity and leveraged buyouts in, 463–510
buyout market, 465–468
LBO scheme and related criticisms, 468
legal environment, 469–480
past debate on legitimacy of, 496–502
2004 reform, impact of, 480–494
Jana Partners, 168
Jenkins Committee (1962), 499
Jensen hypothesis, 315
King Pharmaceuticals, 160–161
Langley Partners, 124–125
Leveraged buyout (LBO) funds, 31–32
Leveraged buyouts (LBOs), 303–308, 311–312, 365, 463–510
impact on productivity, 303–308, 311–312
private equity and, in Italy, 463–510
buyout market, 465–468
LBO scheme and related criticisms, 468
legal environment, 469–480
past debate on legitimacy of, 496–502
2004 reform, impact of, 480–494
Limited partnership structure, 369–373
negotiating the terms, 371
Liquidation preference, 377
Luxembourg, 400, 401, 402, 403, 408
Management buyouts (MBOs), impact on productivity, 303–308, 365
Managers, private equity fund, 59–60, 284–286
deal flow, 286
experience, 286
target and prior funds, difference between, 286
listed, 59–60
performance track record, 286
Market access, enhancing, 387
Maximum Likelihood, 266, 267, 268
Mezzanine capital, 56, 204
Middle-market buyouts, 229–255
background, context, and prior literature, 230–241
descriptive statistics, 234–236
sample and data, 232–233
variables, 233–234
regression results, 241–245
Monte Carlo simulation, 199, 197, 218–221
Mylan Laboratories, 160–161
National Venture Capital Association (NVCA), 339
collection to IPEV guidelines, 341
Netherlands, regulatory responses to hedge fund and private equity in, 389
New Zealand, 402, 403, 405
North America, regional clustering of international PE investment market in, 407
Onex, 261–263275
Pension funds, 10, 11, 12
Peracs Private Equity Selection Efficiency Measure (PESEM), 289, 294
PIPE market, 111–128
contract terms in, 115–118
antidilution protection, 115
company-forced conversion, 117
investor board representation, 116
investor call option, investor right of first refusal, and company put option, 117–118
investor registration rights, 116
redemption rights, 116
trading/hedging restrictions, 116–117
definition, 112–115
distribution of, by industries, 115
firms issuing PIPEs, 118–120
cost of PIPEs, 119
stock performance at closing and in the long run, 119–120
future of, 126–127
investors in, 120–122
issues in, and SEC regulations, 123–126
placement agents, role of, 122
security structure of, 113
Preemptive right, 378
Private equity
  in Canada, 579–602
    multivariate regression evidence, 588–598
    2008 YORKbiotech survey data, description of, 582–588
  in Denmark, 555–578
    history of buyouts, 556–558
    portfolio companies, consequences for capital structure of, 558–565
    tax payments, implications for, 565–575
  in emerging markets, 410–411, 419–436
    determinants of, 421–424
    importance of allocation criteria, survey among institutional investors on, 424–432
    international comparison, 420–421
employment, wage, and productivity effects of transactions, 311–332
employment and productivity identities, 313–315
empirical studies (U.S./U.K.), 315–327
in Europe, 437–461
  history, 438–439
  internationalization of private equity, 446–450
  investment, 441–446
  performance, 450–456
  structure of, 439–441
financing styles, 56
venture capital and, in Germany, 511–553
  German venture capital industry, development of, 513–534
  going public as exit route for venture capital and performance of venture-backed IPOs, 534–548
industry, recent trends in, 33–36
institutional investment in, 9–29
  motivations and behavior, 9–13
  performance, 16–25
  structure and strategies, 13–16
international, 395–417
  fund-raising, brief overview of, 396–398
  investments of private equity funds in western Europe, North America, and Australia, 398–410
  private equity in emerging markets, 410–411
introduction to, 1–6
investment styles, 55–56
investors, types of, 10
in Italy, 463–510
  buyout market, 465–468
  LBO scheme and related criticisms, 468
  legal environment, 469–480
  past debate on legitimacy of, 496–502
  2004 reform, impact of, 480–494
listed, 53–70
  definitions and categorization, 54–60
  direct, 59
  empirical insights on, 60–68
  indirect, 58
  organizational structures of, 57
real effects of, 301–310
  evidence of, 301–307
  research agenda, 307–308
  studies of, 304–305
regulation, comparative analysis of, 359–394
  contractual arrangements, 368–379
  coregulation, 382–384
  growth of private equity, 363
  legal tools, 3886–388
  performance of private equity, 364–365
  regulatory response, 384–386, 388–389
self-regulation, 379–382
returns to, measuring, 17–19, 23–25
  capital flows, 24
  fund size, 23–24
  legality, 24–25
  manager experience, 24
risk, measurement of, 20–25
  multifactor models, 21–23
  single-factor models, 20–21
risk and return of, 257–282
  fund data, 260, 269–270, 272–274
  publicly traded vehicles, 258, 266, 270
  round valuation data, 258–259, 266–269, 270–271
  sample biases, 260, 265–266
  staleness correction, 279–280
stylized model of investment structures, 14
supply-and-demand side of, 365–368
syndication of, 73–92
  future of syndication research, 85–89
  motives for, 75–78
  partner selection, 78–81
  and performance, 85–86
  structuring and managing, 81–84
unlisted, 56–58
  organizational structures of, 57
Private equity firms, geographical concentration of top 50, 35
Private equity funds, 14
  CalPERS report, 274
  managers, 59–60, 284–286
    deal flow, 286
    experience, 286
    focal and prior funds, difference between, 286
    listed, 59–60
    performance track record, 286
INDEX

607

performance, projection of, 197–228
related literature, 199–201
and risk management, simulation approach for, 201–221
simulation results for two fictitious venture capital funds, 221–224
potential reporting biases of, 345–346
publicly traded, 259
reporting biases of valuation, 348–352
selection, 283–299
advanced benchmarking, 290–297
future performance, factors correlated with, 286–287
hypothesis development, 284–285
measurement and operationalization, 285–286
measuring efficiency, approach to, 287–288
Peracs Private Equity Selection Efficiency Measure™ (PESEM), 289
performance-based selection rules, efficiency of, 289–290
public market benchmarks, using and interpreting, 291–292
research approach, 285
traditional benchmarking approach, shortcomings of, 290–291
structure of venture capital and, 93–109
empirical tests, 99–105
optimal effort levels, 94–98
optimal portfolio size and profit-sharing rule, 98–99
Private Equity Monitor (PEM®), 482–486
Private placements by small public entities (Canada), 129–153
Canadian stock market, 130
discounts, 146–149
and long-run performance, 148–149
measure and stylized facts, 147–148
previous evidence and explanations, 146–147
regulation of, in Canada, 131–132
issuers, 132–140
financing strategies and clustering of issuers, 136–137
industry clustering, 135–136
operating performance, 137–138
postplacement performance, 139–140
preissue performance, 138–139
returns surrounding, 140–146
abnormal returns, estimation of, 140–141
differences in long-run performance, analysis of, 145
postissue return of public investors, 144–145
preissue return of public investors, 141–143
Prudent Man Rule, 31
Public Market Equivalent (PME), 67–68
Regression analysis, 103–105
Regulation D, 112–113, 120, 127
Regulatory response, 384–386, 388–389
Canada, 388
Germany, 388–389
Netherlands, 389
United Kingdom, 389
Risk, measurement of, 20–25, 267–268
abnormal performance and, 267–268
multifactor models, 21–23
beta estimates, 22
single-factor models, 20–21
beta estimates, 21
Risk reduction, 76–77
improved deal selection, 76–77
value added, 77
Risk sharing, 75–76
SAC Capital Advisors, 168
Scandinavia, regional clustering of international PE investment market in, 406–407
Schedule 13D, 163–165
Seasoned equity offerings (SEOs), 111
SEC vs. Rhino Advisers, 125
Sedona Corporation, 125
Shane, Hilary L., 123–124
Small business investment companies (SBICs), 365
Sovereign wealth funds, 16, 33
complementing and substituting for private equity investments, 45–48
major, 46
Spain, 400, 402, 403, 404, 405
Stabilization funds. See Sovereign wealth funds
Staleness correction, 279–280
Subprime mortgage crisis, 37–38
Sweden, 400, 402, 403, 404, 405, 409
Swensen, David, 279
Switzerland, 400–401
Syndication of private equity, 73–92
future of syndication research, 85–89
club deals, 87
cross-border syndicates, 87–89
financial distress, 87
interaction between debt and equity, 87
secondary buyouts, 89
motives for, 75–78
access to deal flow, 77–78
risk reduction, 76–77
risk sharing, 75–76
partner selection, 78–81
and performance, 85–86
Syndication of private equity (Continued)
structuring and managing, 81–84
contractual enforcement, 82–83
decision making, 84
equity ownership structure, 81
investees, monitoring of, 83
investment agreement, 81–82

Three-Factor Pricing Model (TFPM), 140. See also Fama-French model
3i Group, 41–44, 259
Time Warner, Inc., 156, 160, 161, 163
Carl Icahn, versus, clinical study of, 167–182
Total value to paid-in (TVPI), 364, 452
United Kingdom, 400, 401, 402, 403, 404, 405, 406, 409. See also Europe, private equity in regulatory responses to hedge fund and private equity in, 389

Valuation and financial disclosure in the private equity industry, 335–357
disclosure and reporting patterns of venture-backed portfolio firms, 347–352
reporting biases of private equity funds valuation, 348–352
institutional setup, 337–342
guidelines for private equity funds, 339–342
main problems and conflicts of interest, 342–343
rules for privately held (portfolio) firms, 337–339

voluntary versus mandatory disclosure, incentives for, 343–347
financial standards, disclosure, and regulation, 346–347
firm-specific information, disclosure of, 344–345
potential reporting biases of private equity funds, determinants of, 345–346
Venture capital (VC), 437
in Canada, 579–602
multivariate regression evidence, 588–598
2008 YORKbiotech survey data, description of, 582–588
funds, 31–33, 365–368
corporate, 365
in Germany, 511–553
German venture capital industry, development of, 513–534
going public as exit route for venture capital and performance of venture-backed IPOs, 534–548
and private equity portfolios, structure of, 93–109
empirical tests, 99–105
optimal effort levels, 94–98
optimal portfolio size and profit-sharing rule, 98–99
Venture capital trusts (VCTs), 440
VentureXpert (Thomson Financial), 17–18, 265
summary cash-flow data, 273

Walker Guidelines, 381–382, 383
Wendy’s International, Inc., 165